

1 Tyler J. Woods (State Bar No. 232464)
twoods@trialnewport.com
2 Richard H. Hikida (State Bar No. 196149)
rhikida@trialnewport.com
3 Scott J. Ferrell (State Bar No. 202091)
sferrell@trialnewport.com
4 **NEWPORT TRIAL GROUP**
A Professional Corporation
5 4100 Newport Place, Suite 800
Newport Beach, CA 92660
6 Tel: (949) 706-6464
Fax: (949) 706-6469
7

8 Attorneys for Plaintiffs

9
10 **UNITED STATES DISTRICT COURT**
11 **SOUTHERN DISTRICT OF CALIFORNIA**

12 THERMOLIFE INTERNATIONAL, LLC,
and THE BOARD OF TRUSTEES OF
13 THE LELAND STANFORD JUNIOR
UNIVERSITY,

14 Plaintiffs,

15 vs.

16 DYMATIZE ENTERPRISES, LLC,

17 Defendants

Case No. 13-cv-888 JLS (MDD)

**AMENDED COMPLAINT FOR
PATENT INFRINGEMENT**

JURY TRIAL DEMANDED

1 Plaintiffs ThermoLife International, LLC and The Board of Trustees of the
2 Leland Stanford Junior University (“Plaintiffs”) hereby allege for their Complaint
3 against Dymatize Enterprises, LLC (“Defendant”), on personal knowledge as to their
4 own activities and on information and belief as to the activities of others, as follows:

5 **I. THE PARTIES**

6 1. Plaintiff ThermoLife International, LLC (“ThermoLife”) is a limited
7 liability company organized and existing under the laws of Arizona, with a place of
8 business at 1811 Ocean Front Walk in Venice, California, 90291.

9 2. Plaintiff The Board of Trustees of the Leland Stanford Junior University
10 (“Stanford University”) is an institution of higher education having powers under the
11 laws of the State of California, with a place of business at 1705 El Camino Real in
12 Palo Alto, California, 94306-1106.

13 3. ThermoLife is and was at all relevant times the exclusive licensee of the
14 following United States Patents:

- 15 a. Patent No. 6,117,872, titled “Enhancement of Exercise Performance
16 by Augmenting Endogenous Nitric Oxide Production or Activity”;
17 b. Patent No. 5,891,459, titled “Enhancement of Vascular Function By
18 Modulation of Endogenous Nitric Oxide Production or Activity”; and
19 c. Patent No. 7,452,916, titled “Enhancement of Vascular Function By
20 Modulation of Endogenous Nitric Oxide Production or Activity.”

21 4. The above patents are and were owned by Stanford University and
22 ThermoLife exclusively licenses and licensed the patents from Stanford University.
23 ThermoLife is pursuing this action and ThermoLife has the right to join Stanford as a
24 necessary party.

25 5. The above patents are referred to herein as the “patents in suit.”

26 6. ThermoLife has been given the right by Stanford University to institute
27 suit with respect to past, current, and future infringement of the patents in suit,
28 including this suit against Defendant.

1 7. Defendant is a corporation organized and existing under the laws of
2 Texas with a principal place of business at 13737 N. Stemmons Fwy. In Farmers
3 Branch, Texas, 75234.

4 8. Defendant does business as Dymatize Nutrition.

5 **II. JURISDICTION AND VENUE**

6 9. This is an action for patent infringement arising under the patent laws of
7 the United States, Title 35 of the United States Code. Accordingly, this Court has
8 subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338, and 1367.

9 10. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400.

10 11. This Court has personal jurisdiction over Defendant. By way of example
11 and without limitation, Defendant, directly or through intermediaries (including
12 distributors, retailers, and others), makes, manufactures, ships, distributes, advertises,
13 markets, offers for sale, and/or sells dietary supplement products that infringe on one
14 or more claims of the patents in suit (hereinafter the “accused products”), which
15 include without limitation products sold under the “Xpand Xtreme Pump” brand
16 name, in the United States, the State of California, and the Southern District of
17 California.

18 12. By way of further example and without limitation, Defendant has
19 purposefully and voluntarily placed the accused products into the stream of commerce
20 with the expectation that they will be purchased in the Southern District of California,
21 and the products are actually purchased in the Southern District of California.

22 **III. THE DEFENDANT’S INFRINGEMENTS**

23 13. Defendant has committed the tort of patent infringement within the State
24 of California, and more particularly, within the Southern District of California, by
25 virtue of the fact that Defendant has formulated, made, manufactured, shipped,
26 distributed, advertised, offered for sale, and/or sold the accused products in this
27 District, and continues to do so.

28 ///

A. DIRECT INFRINGEMENTS

1
2 14. Defendant's employees, agents, representatives and other persons
3 sponsored by or who endorse Defendant and Defendant's products in advertising and
4 marketing activities, have taken, used, and orally administered the accused products.

5 15. The accused products are formulated, made, manufactured, shipped,
6 distributed, advertised, offered for sale, and sold by Defendant to include certain
7 ingredients that, by virtue of their inclusion in the products, infringe one or more
8 claims of one or more of the patents in suit.

9 16. The accused products are formulated, made, manufactured, shipped,
10 distributed, advertised, offered for sale, and sold by Defendant to include specific
11 ingredients for certain purposes that, by virtue of their inclusion in the products for
12 such purposes, infringe one or more claims of one or more of the patents in suit, and
13 as a result, when Defendant's employees, agents, representatives and other persons
14 sponsored by or who endorse Defendant and Defendant's products in advertising and
15 marketing activities orally administer the accused products, they are practicing and
16 they practiced the methods disclosed in those claims.

17 17. These infringing ingredients, and/or combinations thereof, include,
18 without limitation, Arginine AKG, Arginine HCL, Arginine Ketoisocaproate, and
19 Taurine, as set forth on Defendant's labels for the accused products.

20 18. The purposes for which these ingredients are included in the accused
21 products are and were, without limitation, to enhance nitric oxide production, to
22 improve nitric oxide activity, to produce nitric oxide, to boost nitric oxide levels in the
23 body, and to enhance physical performance.

24 19. Defendant encouraged and/or is aware of the fact that its employees,
25 agents, representatives and other persons sponsored by Defendant or who endorse
26 Defendant and Defendant's products in advertising and marketing activities orally
27 administered and administer the accused products and practice and practiced the
28 methods disclosed in one or more claim of one or more of the patents in suit, and these

1 employees, agents, representatives and other persons sponsored by Defendant or who
2 endorse Defendant and Defendant's products in advertising and marketing activities
3 are and were acting under Defendant's direction and control when practicing those
4 methods.

5 20. Therefore, Defendant is and was a direct infringer of one or more claims
6 of one or more of the patents in suit, and Defendant practices and practiced the
7 methods as set forth in one or more claims of one or more of the patents in suit.

8 **B. INDIRECT INFRINGEMENTS**

9 21. End-users of Defendant's accused products were and are also direct
10 infringers of one or more claims of one or more of the patents in suit.

11 22. End-users of Defendant's accused products have taken, used, and orally
12 administered the accused products.

13 23. The accused products are and were formulated, made, manufactured,
14 shipped, distributed, advertised, offered for sale, and/or sold by Defendant to include
15 certain ingredients that, by virtue of their inclusion in the products, infringe and
16 infringed one or more claims of one or more of the patents in suit.

17 24. The accused products are and were formulated, made, manufactured,
18 shipped, distributed, advertised, offered for sale, and/or sold by Defendant to include
19 specific ingredients for certain purposes that, because of their inclusion in the products
20 for such purposes, infringe and infringed one or more claims of one or more of the
21 patents in suit, and as a result, when end-users of Defendant's accused products orally
22 administer and administered the accused products, they are and were practicing the
23 methods disclosed in those claims.

24 25. Defendant's labels and advertising for the accused products explain and
25 explained the elements and essential elements of one or more of the methods disclosed
26 in the patents in suit, and those labels and advertising statements encourage, urge, and
27 induce the accused products' end-users, and did so in the past, to purchase and orally
28

1 ingest the products to practice those methods, and end-users do and did practice those
2 methods.

3 26. Defendant has therefore specifically intended to cause these end-users to
4 directly infringe the claimed methods of these patents, and in fact urged them to do so.

5 27. The accused products are and were not suitable for non-infringing uses,
6 and none of Defendant's labels or advertisements for the accused products disclose or
7 disclosed any uses for the products, nor for the compounds disclosed in the claimed
8 methods of the patents in suit, that do not infringe upon such methods.

9 28. The inclusion of the specific infringing compounds in the products is and
10 was material to practicing such methods.

11 29. Defendant has and had knowledge that the accused products are and were
12 especially adapted by end-users of the products for the practicing of such methods,
13 and, indeed, Defendant encourages, urges, and induces the accused products' end-
14 users to purchase and orally administer the accused products to practice such methods,
15 and has done so in the past.

16 30. Defendant intentionally and knowingly induced, encouraged, and urged
17 end-users of the accused products to purchase and orally administer the accused
18 products for the purposes of practicing the claimed methods, by having them orally
19 ingest the compounds disclosed in such claims.

20 31. Defendant has and had knowledge of the fact that the accused products,
21 particularly as administered, infringe on one or more claims of the patents in suit.

22 32. Defendant has and had direct, firsthand knowledge of the patents in suit.

23 33. For example and without limitation, Plaintiffs believe Defendant has had
24 knowledge of the patents in suit since November 2006, when an ongoing settlement of
25 a patent infringement case relating to at least some of the patents in suit against
26 Herbalife, a well-known company in Defendant's industry, was announced in press
27 releases issued in a highly publicized manner. Plaintiffs believe Defendant's
28

1 employees, agents, and representatives saw the press releases and were aware of the
2 settlement and thus the patents in suit.

3 34. By way of further example and without limitation, Defendant sold its
4 products through retailers, including online retailers, and those retailers have sold
5 other companies' products whose labels and/or advertisements have been prominently
6 marked with one or more of the patents in suit, by patent number, including without
7 limitation, upon information and belief, the products manufactured and sold by
8 Herbalife, Daily Wellness, and Vitality Research Labs. Defendant's employees,
9 agents, and representatives have seen these labels and advertisements and, thus,
10 Defendant has and had direct knowledge of the patents in suit.

11 35. Defendant brazenly and willfully decided to infringe the patents in suit
12 despite knowledge of the patents' existence and its knowledge of the accused
13 products' infringements of the patents.

14 36. At a minimum, and in the alternative, Plaintiffs plead that Defendant
15 willfully blinded itself to the infringing nature of the accused products' sales.

16 37. Defendant did not cease its own direct infringement, nor its contributory
17 infringement or inducement of infringement by end-users, despite its knowledge of the
18 patents in suit and the end-users' infringing activities with respect to the patents in
19 suit.

20 38. Plaintiffs also believe Defendant is infringing on one or more claims of
21 United States Patent No. 5,428,070 and Patent No. 5,945,452, patents which
22 Defendant has had prior knowledge of and are also licensed exclusively to by Stanford
23 University, to include the right to sue for infringement, and Plaintiffs will seek to
24 amend this Complaint once facts confirming that belief are ascertained.

25 **IV. FIRST CAUSE OF ACTION**

26 **Infringement of U.S. Patent No. 5,891,459**

27 39. Plaintiffs repeat and re-allege the allegations of the foregoing paragraphs
28 of this Complaint as if fully set forth herein.

1 40. Defendant has in the past literally and directly infringed or directly
2 infringed under the doctrine of equivalents one or more claims of United States Patent
3 No. 5,891,459 by making, using, selling, and offering for sale the accused products, or
4 any one of those products.

5 41. In addition to the fact that Defendant makes, uses, sells, and offers for
6 sale the accused products, and did so in the past, further examples of Defendant's
7 direct infringements include, without limitation, the fact that Defendant encouraged
8 and/or is aware of the fact that its employees, agents, representatives and other persons
9 sponsored by or who endorse Defendant and Defendant's products in advertising and
10 marketing activities orally administer the accused products and practice the methods
11 disclosed in one or more claims of United States Patent No. 5,891,459, and these
12 employees, agents, representatives and other persons sponsored by or who endorse
13 Defendant and Defendant's products in advertising and marketing activities acted
14 under Defendant's direction and control when practicing those methods.

15 42. Defendant encouraged and was aware of these persons' oral
16 administration of the accused products for these purposes, these persons are acting
17 under Defendant's direction and control, and therefore Defendant directly practiced
18 the methods disclosed in United States Patent No. 5,891,459.

19 43. End-users of Defendant's accused products were also direct infringers of
20 one or more claims of United States Patent No. 5,891,459.

21 44. End-users of Defendant's accused products have taken, used, and orally
22 administered the accused products.

23 45. The accused products were formulated, made, manufactured, shipped,
24 distributed, advertised, offered for sale, and sold by Defendant to include certain
25 ingredients that, by virtue of their inclusion in the products, infringed one or more
26 claims of United States Patent No. 5,891,459.

27 46. The accused products were formulated, made, manufactured, shipped,
28 distributed, advertised, offered for sale, and sold by Defendant to include specific

1 ingredients for purposes that, by their inclusion in the products for such purposes,
2 infringed one or more claims of United States Patent No. 5,891,459, and as a result,
3 when end-users of Defendant's accused products orally administered the accused
4 products, they were practicing the methods disclosed in one or more claims of that
5 patent.

6 47. Defendant's labels and advertising for the accused products explained the
7 elements and essential elements of the methods disclosed in United States Patent No.
8 5,891,459, and those labels and advertising statements encouraged, urged, and induced
9 the accused products' end-users to purchase and orally ingest the products to practice
10 those methods, and end-users did practice those methods.

11 48. Defendant therefore specifically intended to cause these end-users to
12 directly infringe the claimed methods of United States Patent No. 5,891,459, and had
13 in fact urged them to do so.

14 49. The accused products were not suitable for non-infringing uses, and none
15 of Defendant's labels or advertisements for the accused products disclosed any uses
16 for the products, nor for the compounds disclosed in the claimed methods, that did not
17 infringe upon such methods.

18 50. The inclusion of these specific infringing compounds in the products was
19 material to practicing such methods.

20 51. Defendant had knowledge that the accused products were especially
21 adapted by end-users of the products for the practicing of such methods, and, indeed,
22 Defendant encouraged, urged, and induced the accused products' end-users to
23 purchase and orally administer the accused products to practice such methods.

24 52. Defendant intentionally and knowingly induced, encouraged, and urged
25 end-users of the accused products to purchase and orally administer the accused
26 products for the purposes disclosed in one or more claims of United States Patent No.
27 5,891,459, by having them orally ingest the compounds disclosed in such claims.

28 ///

1 53. Defendant had knowledge of the fact that the accused products,
2 particularly as administered, infringed on one or more claims of United States Patent
3 No. 5,891,459.

4 54. Defendant also had direct, firsthand knowledge of United States Patent
5 No. 5,891,459 itself.

6 55. Defendant's activities were without express or implied license by
7 Plaintiffs.

8 56. As a result of Defendant's acts of infringement, Plaintiffs have suffered
9 and will continue to suffer damages in an amount to be proved at trial.

10 57. As a result of Defendant's acts of infringement, Plaintiffs have been and
11 will continue to be irreparably harmed by Defendant's infringements, which will
12 continue unless Defendant is enjoined by this Court.

13 58. Defendant's past infringements and/or continuing infringements have
14 been deliberate and willful, and this case is therefore an exceptional case, which
15 warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C.
16 § 285.

17 **V. SECOND CAUSE OF ACTION**

18 **Infringement of U.S. Patent No. 7,452,916**

19 59. Plaintiffs repeat and re-allege the allegations of the foregoing paragraphs
20 of this Complaint as if fully set forth herein.

21 60. Defendant has in the past literally and directly infringed or directly
22 infringed under the doctrine of equivalents one or more claims of United States Patent
23 No. 7,452,916 by making, using, selling, and offering for sale the accused products, or
24 any one of those products.

25 61. In addition to the fact that Defendant makes, uses, sells, and offers for
26 sale the accused products, and did so in the past, further examples of Defendant's
27 direct infringements include, without limitation, the fact that Defendant encouraged
28 and/or is aware of the fact that its employees, agents, representatives and other persons

1 sponsored by or who endorse Defendant and Defendant's products in advertising and
2 marketing activities orally administer the accused products and practice the methods
3 disclosed in one or more claims of United States Patent No. 7,452,916, and these
4 employees, agents, representatives and other persons sponsored by or who endorse
5 Defendant and Defendant's products in advertising and marketing activities acted
6 under Defendant's direction and control when practicing those methods.

7 62. Defendant encouraged and was aware of these persons' oral
8 administration of the accused products for these purposes, these persons are acting
9 under Defendant's direction and control, and therefore Defendant directly practiced
10 the methods disclosed in United States Patent No. 7,452,916.

11 63. End-users of Defendant's accused products were also direct infringers of
12 one or more claims of United States Patent No. 7,452,916.

13 64. End-users of Defendant's accused products have taken, used, and orally
14 administered the accused products.

15 65. The accused products were formulated, made, manufactured, shipped,
16 distributed, advertised, offered for sale, and sold by Defendant to include certain
17 ingredients that, by virtue of their inclusion in the products, infringed one or more
18 claims of United States Patent No. 7,452,916.

19 66. The accused products were formulated, made, manufactured, shipped,
20 distributed, advertised, offered for sale, and sold by Defendant to include specific
21 ingredients for purposes that, by their inclusion in the products for such purposes,
22 infringed one or more claims of United States Patent No. 7,452,916, and as a result,
23 when end-users of Defendant's accused products orally administered the accused
24 products, they were practicing the methods disclosed in one or more claims of that
25 patent.

26 67. Defendant's labels and advertising for the accused products explained the
27 elements and essential elements of the methods disclosed in United States Patent No.
28 7,452,916, and those labels and advertising statements encouraged, urged, and induced

1 the accused products' end-users to purchase and orally ingest the products to practice
2 those methods, and end-users did practice those methods.

3 68. Defendant therefore specifically intended to cause these end-users to
4 directly infringe the claimed methods of United States Patent No. 7,452,916, and had
5 in fact urged them to do so.

6 69. The accused products were not suitable for non-infringing uses, and none
7 of Defendant's labels or advertisements for the accused products disclosed any uses
8 for the products, nor for the compounds disclosed in the claimed methods, that did not
9 infringe upon such methods.

10 70. The inclusion of these specific infringing compounds in the products was
11 material to practicing such methods.

12 71. Defendant had knowledge that the accused products were especially
13 adapted by end-users of the products for the practicing of such methods, and, indeed,
14 Defendant encouraged, urged, and induced the accused products' end-users to
15 purchase and orally administer the accused products to practice such methods.

16 72. Defendant intentionally and knowingly induced, encouraged, and urged
17 end-users of the accused products to purchase and orally administer the accused
18 products for the purposes disclosed in one or more claims of United States Patent No.
19 7,452,916, by having them orally ingest the compounds disclosed in such claims.

20 73. Defendant had knowledge of the fact that the accused products,
21 particularly as administered, infringed on one or more claims of United States Patent
22 No. 7,452,916.

23 74. Defendant also had direct, firsthand knowledge of United States Patent
24 No. 7,452,916 itself.

25 75. Defendant's activities were without express or implied license by
26 Plaintiffs.

27 76. As a result of Defendant's acts of infringement, Plaintiffs have suffered
28 and will continue to suffer damages in an amount to be proved at trial.

1 77. As a result of Defendant's acts of infringement, Plaintiffs have been and
2 will continue to be irreparably harmed by Defendant's infringements, which will
3 continue unless Defendant is enjoined by this Court.

4 78. Defendant's past infringements and/or continuing infringements have
5 been deliberate and willful, and this case is therefore an exceptional case, which
6 warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C.
7 § 285.

8 **VI. THIRD CAUSE OF ACTION**

9 **Infringement of U.S. Patent No. 6,117,872**

10 79. Plaintiffs repeat and re-allege the allegations of the foregoing paragraphs
11 of this Complaint as if fully set forth herein.

12 80. Defendant has in the past and still is literally and directly infringing or
13 directly infringing under the doctrine of equivalents one or more claims of United
14 States Patent No. 6,117,872 by making, using, selling, and offering for sale the
15 accused products, or any one of those products, and will continue to do so unless
16 enjoined by this Court.

17 81. In addition to the fact that Defendant makes, uses, sells, and offers for
18 sale the accused products, further examples of Defendant's direct infringements
19 include, without limitation, the fact that Defendant has encouraged and/or is aware of
20 the fact that its employees, agents, representatives and other persons sponsored by or
21 who endorse Defendant and Defendant's products in advertising and marketing
22 activities orally administer the accused products and practice the methods disclosed in
23 one or more claims of United States Patent No. 6,117,872, and these employees,
24 agents, representatives and other persons sponsored by or who endorse Defendant and
25 Defendant's products in advertising and marketing activities are acting under
26 Defendant's direction and control when practicing those methods.

27 82. Defendant has encouraged and is aware of these persons' oral
28 administration of the accused products for these purposes, these persons are acting

1 under Defendant's direction and control, and therefore Defendant is directly practicing
2 the methods disclosed in United States Patent No. 6,117,872.

3 83. End-users of Defendant's accused products are also direct infringers of
4 one or more claims of United States Patent No. 6,117,872.

5 84. End-users of Defendant's accused products have taken, used, and orally
6 administered the accused products.

7 85. The accused products are formulated, made, manufactured, shipped,
8 distributed, advertised, offered for sale, and sold by Defendant to include certain
9 ingredients that, by virtue of their inclusion in the products, infringe one or more
10 claims of United States Patent No. 6,117,872.

11 86. The accused products is formulated, made, manufactured, shipped,
12 distributed, advertised, offered for sale, and sold by Defendant to include specific
13 ingredients for purposes that, by their inclusion in the products for such purposes,
14 infringe one or more claims of United States Patent No. 6,117,872, and as a result,
15 when end-users of Defendant's accused products orally administer the accused
16 products, they are practicing the methods disclosed in one or more claims of that
17 patent.

18 87. Defendant's labels and advertising for the accused products explain the
19 elements and essential elements of the methods disclosed in United States Patent No.
20 6,117,872, and those labels and advertising statements encourage, urge, and induce the
21 accused products' end-users to purchase and orally ingest the products to practice
22 those methods, and end-users do practice those methods.

23 88. Defendant has therefore specifically intended to cause these end-users to
24 directly infringe the claimed methods of United States Patent No. 6,117,872, and has
25 in fact urged them to do so.

26 89. The accused products are not suitable for non-infringing uses, and none
27 of Defendant's labels or advertisements for the accused products disclose any uses for
28

1 the products, nor for the compounds disclosed in the claimed methods, that do not
2 infringe upon such methods.

3 90. The inclusion of these specific infringing compounds in the products is
4 material to practicing such methods.

5 91. Defendant has knowledge that the accused products are especially
6 adapted by end-users of the products for the practicing of such methods, and, indeed,
7 Defendant encourages, urges, and induces the accused products' end-users to purchase
8 and orally administer the accused products to practice such methods, and have done so
9 in the past.

10 92. Defendant has intentionally and knowingly induced, encouraged, and
11 urged end-users of the accused products to purchase and orally administer the accused
12 products for the purposes disclosed in one or more claims of United States Patent No.
13 6,117,872, by having them orally ingest the compounds disclosed in such claims.

14 93. Defendant has knowledge of the fact that the accused products,
15 particularly as administered, infringe on one or more claims of United States Patent
16 No. 6,117,872.

17 94. Defendant also has direct, firsthand knowledge of United States Patent
18 No. 6,117,872.

19 95. Defendant's activities have been without express or implied license by
20 Plaintiff.

21 96. As a result of Defendant's acts of infringement, Plaintiffs have suffered
22 and will continue to suffer damages in an amount to be proved at trial.

23 97. As a result of Defendant's acts of infringement, Plaintiffs have been and
24 will continue to be irreparably harmed by Defendant's infringements, which will
25 continue unless Defendant is enjoined by this Court.

26 98. Defendant's past infringements and/or continuing infringements have
27 been deliberate and willful, and this case is therefore an exceptional case, which
28

1 warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C.
2 § 285.

3 **VII. PRAYER FOR RELIEF**

4 WHEREFORE, Plaintiffs pray for entry of judgment against Defendant as
5 follows:

6 1. A declaration that Defendant has infringed the patents in suit, under 35
7 U.S.C. §§ 271 *et seq.*;

8 2. That injunctions, preliminary and permanent, be issued by this Court
9 restraining Defendant, its officers, agents, servants, directors, and employees, and all
10 persons in active concert or participation with each, from directly or indirectly
11 infringing, or inducing or contributing to the infringement by others of, United States
12 Patent No. 6,117,872;

13 3. That Defendant be required to provide to Plaintiffs an accounting of all
14 gains, profits, and advantages derived by Defendant's infringement of the patents in
15 suit, and that Plaintiffs be awarded damages adequate to compensate Plaintiffs for the
16 wrongful infringing acts by Defendant, in accordance with 35 U.S.C. § 284;

17 4. That the damages awarded to Plaintiffs with regard to the patents in suit
18 be increased up to three times, in view of Defendant's willful infringement, in
19 accordance with 35 U.S.C. § 284;

20 5. That this case be declared to be exceptional in favor of Plaintiffs under 35
21 U.S.C. § 285, and that Plaintiffs be awarded their reasonable attorneys' fees and other
22 expenses incurred in connection with this action;

23 6. That Plaintiffs be awarded their interest and costs of suit incurred in this
24 action;

25 7. Compensatory damages;

26 8. Punitive damages; and

27 ///

28 ///

1 9. That Plaintiffs be awarded such other and further relief as this Court may
2 deem just and proper.

3 Respectfully submitted,
4 NEWPORT TRIAL GROUP
5 A Professional Corporation

6 Dated: February 13, 2014

7 */s/Tyler J Woods*
8 By: Tyler J. Woods
9 Attorneys for Plaintiffs

DEMAND FOR JURY TRIAL

Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiffs hereby demand a jury trial for all issues in this case that properly are subject to a jury trial.

Respectfully submitted,
NEWPORT TRIAL GROUP
A Professional Corporation

Dated: February 13, 2014

/s/Tyler J Woods
By: Tyler J. Woods
Attorneys for Plaintiffs

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

CERTIFICATE OF SERVICE

I hereby certify that on February 13, 2014, I electronically filed the foregoing **THERMOLIFE INTERNATIONAL, LLC GROUP, LLC'S AMENDED COMPLAINT FOR PATENT INFRINGEMENT** with the Clerk of the Court using the CM/ECF system which will send notification of such filing via electronic mail to all counsel of record.

/s/Tyler J Woods
Tyler J Woods

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28